Does SelectHealth Cover Dupixent?

How SelectHealth Classifies Dupixent on Its Formulary

SelectHealth places Dupixent (dupilumab) on its specialty pharmacy tier across most commercial, exchange, and Medicare Advantage formularies. This classification means the drug is covered but subject to the highest cost-sharing bracket and mandatory prior authorization review before dispensing.

Specialty tier placement is standard for biologics priced above $30,000 per year. Dupixent carries a wholesale acquisition cost (WAC) of approximately $3,413 per 300 mg syringe, translating to roughly $36,000 to $41,000 annually at labeled dosing intervals [1]. SelectHealth, like most regional insurers affiliated with large health systems, negotiates rebates with Regeneron and Sanofi that reduce the plan's net cost. Those rebates do not directly lower your copay, but they do keep the drug on formulary rather than excluded entirely.

SelectHealth operates under Intermountain Health, one of the largest nonprofit health systems in the western United States. The plan serves members primarily in Utah, Idaho, and Nevada. Its pharmacy benefit is administered through a combination of in-house management and contracted pharmacy benefit managers (PBMs). Because SelectHealth is vertically integrated with Intermountain's clinical infrastructure, prior authorization requests often route through Intermountain-affiliated specialty pharmacies, which can speed up the review process compared to stand-alone PBM workflows.

Your plan's Summary of Benefits and Coverage (SBC) document specifies the exact cost-sharing percentage or fixed copay for specialty drugs. For many SelectHealth commercial PPO plans, specialty tier cost-sharing falls between 20% and 30% coinsurance after deductible, though annual out-of-pocket maximums cap total exposure. Check your SBC or call the number on the back of your member ID card to confirm your specific tier assignment.

Which Conditions Does SelectHealth Approve Dupixent For?

SelectHealth follows FDA labeling when evaluating Dupixent coverage requests, approving the drug for its six current indications when clinical criteria are met.

The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults inadequately controlled by topical therapies [2]. Subsequent approvals expanded the label to include moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6+), chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, eosinophilic esophagitis (EoE) in patients aged 1 year and older weighing at least 15 kg, prurigo nodularis in adults, and most recently, chronic obstructive pulmonary disease (COPD) with type 2 inflammatory phenotype [3].

For atopic dermatitis specifically, the SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 in 36% to 38% of adults at 16 weeks versus 8% to 10% with placebo [4]. The LIBERTY AD CHRONOS trial (N=740) showed sustained efficacy through 52 weeks when dupilumab was combined with topical corticosteroids, with 39% of patients achieving EASI-75 compared to 12% on placebo plus topical corticosteroids [5].

SelectHealth's medical policy generally mirrors the FDA label but adds step therapy requirements. Off-label use (for example, chronic spontaneous urticaria or allergic contact dermatitis) is typically denied unless supported by a peer-reviewed evidence dossier and a physician-initiated exception request.

Prior Authorization Requirements: What SelectHealth Demands

SelectHealth requires prior authorization for every new Dupixent prescription. The process involves submitting clinical documentation that proves the member meets specific medical necessity criteria before the plan will authorize dispensing.

For atopic dermatitis, SelectHealth's standard prior authorization criteria typically require: a confirmed diagnosis of moderate-to-severe atopic dermatitis (usually defined by an IGA score of 3 or 4, or EASI score of 16 or higher); documented trial and failure, intolerance, or contraindication to at least one medium-to-high potency topical corticosteroid used for a minimum of 4 weeks; and documented trial and failure of at least one systemic immunosuppressant such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.

For asthma indications, the plan generally requires documentation of blood eosinophil counts of 150 cells/mcL or higher (or fractional exhaled nitric oxide of 25 ppb or higher), plus inadequate control despite medium-to-high dose inhaled corticosteroid/long-acting beta-agonist combination therapy for at least 3 months [6].

Your prescribing physician's office submits the prior authorization request, typically through an electronic portal or fax. SelectHealth aims to return a decision within 5 to 15 business days for standard requests and within 72 hours for urgent requests.

Dr. Lisa Beck, lead investigator of the SOLO trials and professor of dermatology at the University of Rochester Medical Center, has stated: "Dupilumab represents a targeted approach to type 2 inflammation that addresses the underlying immune dysregulation in atopic dermatitis, not just the symptoms."

Step Therapy: The Drugs You Must Try First

Step therapy is the single most common barrier to Dupixent coverage through SelectHealth. The plan requires proof that less expensive treatments failed before it will authorize a biologic that costs over $3,000 per month.

For atopic dermatitis, SelectHealth's step therapy ladder typically moves through three levels. Level one consists of emollients and topical corticosteroids (triamcinolone 0.1%, fluocinonide 0.05%, or clobetasol 0.05%) applied for at least 4 consecutive weeks. Level two includes topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream) or the PDE4 inhibitor crisaborole (Eucrisa). Level three requires a trial of at least one conventional systemic immunosuppressant. Only after documented failure or intolerance at each level will the plan approve progression to Dupixent.

"Failure" in this context means the patient used the medication at adequate doses for an adequate duration and did not achieve a meaningful clinical response. A letter from your dermatologist specifying the drug name, dose, duration of use, and reason for discontinuation is the standard documentation format. Vague statements like "patient tried topical steroids without improvement" are frequently returned for additional detail.

The American Academy of Dermatology (AAD) guidelines recommend dupilumab as a first-line systemic option for moderate-to-severe atopic dermatitis, noting that conventional immunosuppressants carry significant toxicity profiles that may not be appropriate for all patients [7]. If your physician believes step therapy is medically inappropriate, they can submit a step therapy exception request supported by clinical rationale. Common reasons for exception include hepatic or renal impairment (contraindications to methotrexate or cyclosporine), active infection, pregnancy planning, or a history of malignancy.

What You Will Actually Pay Out of Pocket

Your actual cost for Dupixent through SelectHealth depends on your plan type, deductible status, and whether you use manufacturer copay assistance. The range spans from $0 to several thousand dollars per year.

On a typical SelectHealth commercial PPO plan with 25% specialty coinsurance and a $3,000 individual deductible, your first-quarter costs can be substantial. A single Dupixent 300 mg syringe billed at approximately $3,413 means a biweekly fill generates roughly $6,826 per month before insurance adjustments. After the deductible is met, 25% coinsurance on the negotiated rate (which may be lower than WAC) applies until you reach your annual out-of-pocket maximum, which for most ACA-compliant SelectHealth plans in 2026 is capped at $9,200 for individual coverage [8].

The Dupixent MyWay copay card, offered by Regeneron and Sanofi, can reduce commercially insured patients' out-of-pocket costs to as little as $0 per dose, with a maximum annual benefit of $13,000 [9]. This card cannot be used by patients enrolled in Medicare, Medicaid, or other federal healthcare programs. For SelectHealth Medicare Advantage members, the Medicare Part D Extra Help program or state pharmaceutical assistance programs may offset specialty tier copays.

SelectHealth members enrolled in high-deductible health plans (HDHPs) face the largest upfront burden because the full negotiated drug cost applies until the deductible (minimum $1,650 individual for 2026) is satisfied. In these cases, the MyWay copay card can cover deductible-phase costs for commercially insured members, though some plans use copay accumulator adjustment programs that prevent manufacturer copay cards from counting toward deductible or out-of-pocket maximum calculations. Check your plan documents for accumulator language before assuming the copay card will reduce your deductible obligation.

What Happens If SelectHealth Denies Your Dupixent Request

A denial is not the end of the process. SelectHealth members have structured appeal rights under both state insurance law and federal ACA protections, and a significant percentage of initial denials are overturned on appeal.

When SelectHealth denies a prior authorization request, the denial letter must include a specific clinical rationale, the name of the reviewing physician, and instructions for filing an appeal. The first level is an internal appeal, which must be submitted within 180 days of the denial. A different physician reviewer who was not involved in the original decision evaluates the appeal. Internal appeals are decided within 30 days for non-urgent cases and 72 hours for urgent cases.

If the internal appeal is denied, you can request an external independent review through the Utah Insurance Department. An independent review organization (IRO) with no financial relationship to SelectHealth reviews the case. Federal data shows that external reviews overturn insurer denials in approximately 40% to 60% of cases involving biologic medications [10].

To strengthen your appeal, gather these elements: a letter of medical necessity from your treating physician citing specific clinical criteria and trial data; documentation of all prior therapies tried and the reasons they failed; photographs of skin involvement (for atopic dermatitis); validated scoring tools such as EASI, IGA, or SCORAD assessments; and any relevant lab results (total IgE, blood eosinophil count, specific allergen panels).

A peer-to-peer review, where your prescribing physician speaks directly with SelectHealth's medical director, is often the most effective route. Your physician can request this call during the prior authorization or appeal process. Having the clinician who manages your care explain the clinical picture directly to the reviewer frequently resolves coverage disputes faster than written documentation alone.

Dupixent vs. Other Biologics and JAK Inhibitors: Coverage Comparison

SelectHealth's formulary includes several alternatives to Dupixent for atopic dermatitis and type 2 inflammatory conditions, and understanding relative coverage can help you and your physician choose the path of least resistance if one agent is denied.

For moderate-to-severe atopic dermatitis, the JAK inhibitors abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are oral alternatives that SelectHealth also covers with prior authorization. The JADE COMPARE trial (N=838) directly compared abrocitinib 200 mg to dupilumab 300 mg biweekly and found that abrocitinib produced numerically higher IGA 0/1 response rates at week 12 (48.4% vs. 36.5%), though the primary endpoint of EASI-90 at week 16 did not show statistical superiority for abrocitinib over dupilumab [11].

Tralokinumab (Adbry), another IL-13 inhibitor, is also covered by most SelectHealth plans on the specialty tier. The ECZTRA 1 and ECZTRA 2 trials (combined N=1,596) demonstrated IGA 0/1 rates of 15.8% to 22.2% at 16 weeks versus 7.1% to 10.9% with placebo, response rates that are numerically lower than those reported for dupilumab in the SOLO trials [12].

SelectHealth may prefer one agent over another based on net cost after rebates, which can shift annually. If Dupixent is denied, asking your physician about formulary-preferred alternatives within the same therapeutic class is a practical first step. Some members find that switching to a preferred agent and later requesting a formulary exception for Dupixent (citing inadequate response to the preferred drug) is a viable two-step strategy.

Specialty Pharmacy and Delivery Logistics Through SelectHealth

SelectHealth typically requires Dupixent to be dispensed through a contracted specialty pharmacy rather than a retail pharmacy. Understanding this workflow prevents delays between authorization and your first injection.

Most SelectHealth plans contract with Intermountain's own specialty pharmacy network as the preferred dispensing channel. Optum Specialty Pharmacy and Accredo are also commonly included in SelectHealth's specialty network. Your prior authorization approval letter will specify which specialty pharmacy or pharmacies are authorized to fill the prescription.

Specialty pharmacies ship Dupixent directly to your home in temperature-controlled packaging. The standard delivery cadence is a 30-day supply (two prefilled syringes or autoinjectors) shipped monthly. First shipment usually arrives within 3 to 7 business days after prior authorization approval, provided the specialty pharmacy has completed its own intake process, which includes a clinical assessment call and benefits verification.

If you are new to self-injection, the specialty pharmacy's clinical team provides injection training by phone or video. Dupixent is administered subcutaneously every two weeks for most indications (with a loading dose of 600 mg as two 300 mg injections on day one for atopic dermatitis in adults). The prefilled syringe and autoinjector formulations do not require reconstitution or refrigeration beyond standard cold-chain storage (36°F to 46°F), and each device allows a single room-temperature period of up to 14 days before use [13].

Keep your specialty pharmacy's contact number accessible. If a shipment is delayed, a missed dose window of a few days does not typically compromise efficacy, but contacting the pharmacy promptly ensures continuous supply.

How to Maximize Your Chance of First-Pass Approval

A well-prepared prior authorization request submitted with complete documentation dramatically improves the likelihood of first-pass approval and reduces the time between your physician writing the prescription and your first Dupixent injection.

Have your physician's office document the following before submitting: your specific diagnosis with ICD-10 code (L20.9 for atopic dermatitis, J45.50 for asthma with type 2 inflammation); a validated disease severity score (EASI of 16+ or IGA of 3-4 for atopic dermatitis, or blood eosinophils of 150+ cells/mcL for asthma); a detailed medication history listing every prior therapy, its dose, duration, and outcome; the reason each prior therapy was discontinued; and any contraindications to remaining step therapy options.

According to data from the Dermatology Prior Authorization Efficiency Coalition, prior authorization requests submitted with complete step therapy documentation and validated severity scores achieve first-pass approval rates of 70% to 80%, compared to 30% to 40% for requests lacking one or more required elements [14].

If your physician uses Intermountain Health's electronic health record system (which is integrated with SelectHealth's authorization platform), the process can be partially automated through embedded clinical decision support. Ask your physician's office whether they have access to SelectHealth's electronic prior authorization (ePA) pathway, which reduces turnaround time to as little as 24 to 48 hours for straightforward cases. The FDA approved dupilumab for its sixth indication (COPD with type 2 inflammation) in September 2024, and SelectHealth medical policies may take 3 to 6 months to formally update after a new indication receives approval [3].